Updated 13/09/2026
The World Health Organization has released new strategic guidance designed to help countries develop and implement national responses to fungal disease and antifungal resistance, addressing what the organisation describes as one of the most neglected yet significant global health challenges. Despite the scale of the threat, fungal infections remain largely absent from most national health plans, according to WHO’s assessment.
Key takeaways
- WHO has published new guidance to help countries tackle fungal disease and antifungal resistance, a largely neglected global health threat
- Fungal infections are currently missing from most national health plans despite their growing burden on healthcare systems
- The new action plan emphasises surveillance, laboratory capacity-building, and integration of antifungal stewardship into existing health frameworks
Fungal disease burden: key gaps in global response
Percentage of countries reporting key fungal disease capacities
Source: WHO Global Fungal Disease Assessment, 2026 | Georgian Medical Journal News
A neglected threat gaining urgency
Fungal infections kill an estimated 1.5 million people annually and affect hundreds of millions more, yet remain conspicuously absent from global disease surveillance priorities and national healthcare agendas. According to the WHO’s 2026 assessment, fewer than one in five countries have integrated fungal disease into their national health strategies, despite the documented rise in both incidence and treatment-resistant cases.
The oversight is particularly consequential because fungal diseases disproportionately affect immunocompromised populations, including people living with HIV/AIDS, those on immunosuppressive therapy, and critically ill hospital patients. WHO emphasises that the absence of coordinated surveillance means the true global burden remains unmeasured.
Key components of the new WHO guidance
The new action plan outlines four strategic pillars: strengthening surveillance and epidemiological data collection; building diagnostic and laboratory capacity in resource-limited settings; establishing antifungal stewardship programmes; and integrating fungal disease management into existing antimicrobial resistance frameworks.
Central to the guidance is the recommendation that countries conduct baseline assessments of their current mycology laboratory infrastructure and diagnostic capabilities. WHO guidance documents stress that many low- and middle-income countries lack the equipment and trained personnel required to identify and characterise fungal pathogens, creating blind spots in disease surveillance.
Fewer than one in five countries currently have fungal disease integrated into national health plans, despite annual mortality estimates exceeding 1.5 million deaths globally.
— World Health Organization, 2026 Global Fungal Disease Assessment
Antifungal resistance: the emerging crisis
Parallel to rising fungal disease burden is the documented emergence of antifungal-resistant strains, particularly among Candida auris and Aspergillus fumigatus species. These resistance patterns are being detected across multiple continents, yet remain poorly tracked in most national surveillance systems. The lack of coordinated monitoring means resistant strains can spread unchecked across healthcare systems and borders.
WHO’s new guidance advocates for the integration of antifungal stewardship principles into broader antimicrobial stewardship frameworks already in place in many countries. This approach leverages existing infrastructure while ensuring antifungal resistance receives dedicated attention and resources. The guidance also recommends standardised susceptibility testing protocols and regional reference laboratory networks to enable rapid identification of resistance patterns.
Implementation pathways for countries
The new WHO action plan is structured to accommodate countries at different stages of health system capacity. For countries beginning their response, WHO recommends establishing a national fungal disease coordination mechanism and conducting a baseline assessment of laboratory and diagnostic resources. Intermediate steps include developing national fungal disease surveillance protocols and integrating fungal disease indicators into existing antimicrobial resistance monitoring systems.
WHO also emphasises the importance of regional laboratory networks, particularly in sub-Saharan Africa and Southeast Asia, where fungal disease burden is high but diagnostic infrastructure remains limited. Access to category pages on global health initiatives and health policy implementation provides additional context on international response frameworks.
What this means
Frequently asked questions
Why is fungal disease considered neglected despite its high mortality burden?
Fungal infections have historically received less attention than bacterial or viral diseases in global health policy, partly because they affect specific high-risk populations and lack the dramatic outbreak profile of epidemic pathogens. Additionally, diagnostic capacity in many countries is insufficient to detect and track fungal cases systematically, making the true burden invisible to policymakers. Global health initiatives are now working to elevate fungal disease to the same priority level as other antimicrobial resistance threats.
What is antifungal resistance and why does it matter?
Antifungal resistance occurs when fungal pathogens develop the ability to survive exposure to antifungal medications, making infections harder or impossible to treat. This is particularly concerning because the pipeline of new antifungal drugs is limited compared to antibiotics. Without coordinated surveillance and stewardship, resistant strains spread rapidly through healthcare systems and communities, creating untreatable infections in vulnerable populations.
How can countries with limited laboratory capacity implement this WHO guidance?
WHO’s action plan is designed with tiered implementation in mind. Countries can begin by establishing coordination mechanisms and conducting capacity assessments, then gradually build laboratory infrastructure through regional networks and capacity-building partnerships. The guidance emphasises using existing antimicrobial resistance surveillance frameworks rather than creating parallel systems, allowing countries to integrate fungal disease monitoring into already-funded programmes.
As countries move to implement WHO’s new action plan, the emphasis will be on building sustainable capacity within existing health systems rather than creating parallel programmes. Early adoption of surveillance and stewardship protocols will generate epidemiological data that can inform resource allocation and clinical practice guidelines. The next phase will be tracking implementation progress and outcomes to refine the approach based on real-world experience in diverse healthcare settings.
Source: WHO launches new action plan to combat fungal disease and antifungal resistance, UN News, June 2026
🗺️ Find certified Georgian healthcare providers: sheniekimi.ge — Georgia Health Map · 998 clinics · 6,600+ doctors · 2,296 pharmacies
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
